文献速递性腺与生殖内分泌

男性先天性低促性腺激素性性腺功能减退症患者逆转的分类与预测因素:六家国际转诊中心的横断面研究

Classes and predictors of reversal in male patients with congenital hypogonadotropic hypogonadism: a cross-sectional study of six international referral centres.
PubMed 文献 · Lancet Diabetes Endocrinol · 2024-03-01

这项多中心横断面研究纳入87例先天性低促性腺激素性性腺功能减退症(CHH)逆转男性和108例无逆转男性,用潜类别混合模型识别出两种逆转类别,并发现嗅觉缺失、隐睾、青春期完全缺失、寡基因变异及ANOS1、GNRHR罕见变异与逆转相关。

要点

  • CHH逆转存在两个 distinct 类别:类别1占86%,类别2占14%,后者睾丸体积更大、无小阴茎、FSH更高。
  • 无逆转者更常见嗅觉缺失、隐睾、青春期完全缺失(睾丸体积<4 cm³)及≥2个罕见遗传变异。
  • 逆转者中GNRHR罕见变异比例更高(12% vs 3%),而ANOS1罕见变异仅见于无逆转者(0/75 vs 10/95)。

核心结论

  • 对CHH逆转男性应用潜类别混合模型识别出两个 distinct 逆转类别,遗传学检查结合仔细临床表型可能有助于停药后逆转的监测,代表针对该罕见内分泌疾病男性患者的首个定制化管理方法。

研究设计与样本

  • 多中心横断面研究,在巴西、芬兰、法国、意大利、英国和美国的六家国际CHH转诊中心开展,纳入87例CHH逆转男性和108例无逆转男性,使用COST Action BM1105开发的结构化统一数据收集表收集表型、临床评估和遗传学数据,采用潜类别混合模型分析。

主要发现

  • 潜类别混合模型基于平均睾丸体积、小阴茎和血清卵泡刺激素(FSH)浓度识别出两个 distinct 逆转类别:类别1为75例(86%),类别2为12例(14%)。
  • 分类概率稳健(类别1为0.998,类别2为0.838),模型不确定性低(熵0.90)。
  • 与类别1相比,类别2患者睾丸体积显著更大(p<0.0001)、无小阴茎、血清FSH浓度更高(p=0.041),符合CHH的Pasqualini综合征(有生育能力的宦官)亚型。
  • 无CHH逆转者更可能有嗅觉缺失(p=0.016)、隐睾(p=0.0012)、青春期完全缺失(睾丸体积<4 cm³;p=0.0016)和两个或以上罕见遗传变异(即寡基因性;p=0.0001)。
  • 在接受遗传学检测的患者中,CHH逆转者无一人(0/75)携带罕见致病性ANOS1变异,而无逆转者为95例中的10例(11%);CHH逆转者GNRHR罕见变异比例显著更高(75例中9例[12%] vs 95例中3例[3%];p=0.025)。

关键数值与推荐

  • CHH逆转定义为停用治疗后下丘脑-垂体-性腺(HPG)轴功能自发恢复。
  • 纳入标准为成年男性CHH患者,即18岁时无自发青春期或青春期不完全、血清睾酮浓度低、无可识别的原因导致HPG轴功能障碍。
  • 逆转类别基于平均睾丸体积、小阴茎和血清FSH浓度区分;类别1为75例(86%),类别2为12例(14%)。
  • 无逆转者更可能有嗅觉缺失(p=0.016)、隐睾(p=0.0012)、青春期完全缺失(睾丸体积<4 cm³;p=0.0016)和≥2个罕见遗传变异(p=0.0001)。
  • CHH逆转者GNRHR罕见变异比例为12%(9/75),无逆转者为3%(3/95),p=0.025;CHH逆转者ANOS1罕见致病性变异为0/75,无逆转者为10/95(11%)。

临床怎么用

  • 作者认为,遗传学检查结合仔细临床表型可能有助于停药后逆转的监测,代表针对该罕见内分泌疾病男性患者的首个定制化管理方法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although some male patients with congenital hypogonadotropic hypogonadism (CHH) undergo spontaneous reversal following treatment, predictors of reversal remain elusive. We aimed to assemble the largest cohort of male patients with CHH reversal to date and identify distinct classes of reversal. METHODS: This multicentre cross-sectional study was conducted in six international CHH referral centres in Brazil, Finland, France, Italy, the UK, and the USA. Adult men with CHH (ie, absent or incomplete spontaneous puberty by age 18 years, low serum testosterone concentrations, and no identifiable cause of hypothalamic-pituitary-gonadal [HPG] axis dysfunction) were eligible for inclusion. CHH reversal was defined as spontaneous recovery of HPG axis function off treatment. Centres provided common data elements on patient phenotype, clinical assessment, and genetics using a structured, harmonised data collection form developed by COST Action BM1105. Latent class mixture modelling (LCMM) was applied to establish whether at least two distinct classes of reversal could be identified and differentially predicted, and results were compared with a cohort of patients without CHH reversal to identify potential predictors of reversal. The primary outcome was the presence of at least two distinct classes of reversal. FINDINGS: A total of 87 male patients with CHH reversal and 108 without CHH reversal were included in the analyses. LCMM identified two distinct reversal classes (75 [86%] in class 1 and 12 [14%] in class 2) on the basis of mean testicular volume, micropenis, and serum follicle-stimulating hormone (FSH) concentration. Classification probabilities were robust (0·998 for class 1 and 0·838 for class 2) and modelling uncertainty was low (entropy 0·90). Compared with class 1, patients in class 2 had significantly larger testicular volume (p<0·0001), no micropenis, and higher serum FSH concentrations (p=0·041), consistent with the Pasqualini syndrome (fertile eunuch) subtype of CHH. Patients without CHH reversal were more likely to have anosmia (p=0·016), cryptorchidism (p=0·0012), complete absence of puberty (testicular volume <4 cm³; p=0·0016), and two or more rare genetic variants (ie, oligogenicity; p=0·0001). Among patients who underwent genetic testing, no patients (of 75) with CHH reversal had a rare pathogenic ANOS1 variant compared with ten (11%) of 95 patients without CHH reversal. Individuals with CHH reversal had a significantly higher rate of rare variants in GNRHR than did those without reversal (nine [12%] of 75 vs three [3%] of 95; p=0·025). INTERPRETATION: Applying LCMM to a large cohort of male patients with CHH reversal uncovered two distinct classes of reversal. Genetic investigation combined with careful clinical phenotyping could help surveillance of reversal after withdrawing treatment, representing the first tailored management approach for male patients with this rare endocrine disorder. FUNDING: National Institutes of Health National Center for Advancing Translational Sciences; Ministry of Health, Rome, Italy; Ministry of University, Rome, Italy; National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development; and the Josiah Macy Jr Foundation. TRANSLATION: For the Italian translation of the abstract see Supplementary Materials section.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Dwyer AA, McDonald IR, Cangiano B, et al. Classes and predictors of reversal in male patients with congenital hypogonadotropic hypogonadism: a cross-sectional study of six international referral centres. Lancet Diabetes Endocrinol. 2024. PMID: 38437850. doi:10.1016/S2213-8587(24)00028-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。